The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: Findings and implications

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 2, 2015, Pages 279-289

  Fürst, Jurij ^a   Čižman, Milan ^b   Mrak, Jana ^a   Kos, Damjan ^a   Campbell, Stephen ^c,d   Coenen, Samuel ^e   Gustafsson, Lars L ^f   Fürst, Luka ^g   Godman, Brian ^f,h  

^a Health Insurance Institute of Slovenia   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF LJUBLJANA   (Slovenia)

^h UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

antibiotic resistance; antibiotic use; drug utilization; multifaceted interventions; policies; rational use of antibiotics; Slovenia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; LINCOSAMIDE; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN V; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG USE; ESCHERICHIA COLI; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NONHUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY; SLOVENIA; STREPTOCOCCUS PNEUMONIAE; CLINICAL PRACTICE; DRUG EFFECTS; DRUG UTILIZATION; ECONOMICS; FOLLOW UP; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; SLOVENIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84924731943     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.990381     Document Type: Article

References (61)

1. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood) 2010;29(9):1689-96
2. Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA 2011; 305(10):1027-8
3. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:Cd003543
4. Sabuncu E, David J, Bernede-Bauduin C, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009;6(6):e1000084
5. Huttner B, Goossens H, Verheij T, Harbarth S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis 2010;10(1):17-31
6. Ganguly NK, Arora NK, Chandy SJ, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94
7. WeMeReC Bulletin. Appropriate antibiotic use-whose responsibility? Available from: www.wemerec.org/Documents/Bulletins/AntibioBulletin2012Online.pdfNovember
8. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13(12): 1057-98
9. Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China-a major future challenge. Lancet 2009;373(9657):30
10. World Health Organisation. WHO global strategy for containment of antimicrobial resistance. 2001. Available from: www.who. int/csr/resources/publications/drugresist/en/EGlobal-Strat.pdf]
11. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9459):579-87
12. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ (Clinical research ed) 2010;340:c2096
13. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009;15(Suppl 3)):12-15
14. Cizman M, Pokorn M, Seme K, et al. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999;18(7):522-4
15. Department of Health, Social Services and Public Safety Northern Ireland. A strategy for changing antimicrobial resistance (STAR) 2012 to 2017. Available from: www.dhsspsni.gov.uk/star-doc.pdf
16. Standing Medical Advisory Committee. The Path of Least Resistance. http://antibioticaction. com/wp-content/uploads/2011/07/Standing-Medical-Advisory-Committee-Thepath-of-least-resistance-1998.pdf
17. Molstad S, Cars O, Struwe J. Strama-a Swedish working model for containment of antibiotic resistance. Euro Surveill 2008; 13:46
18. Adriaenssens N, Coenen S, Tonkin-Crine S, et al. European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Qual Saf 2011. [Epub ahead of print]
19. Goossens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol 2006;62(5): 373-9
20. Cals JW, Butler CC, Hopstaken RM, et al. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ (Clinical research ed) 2009;338:b1374
21. Little P, Stuart B, Francis N, et al. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet 2013;382(9899):1175-82
22. Cizman M, Srovin T, Pokorn M, et al. Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia. J Antimicrob Chemother 2005;55(5):758-63
23. Bajcetic M, Kalaba M, Godman B, Sipetic T, et al. Ongoing programmes to reduce the high rate of antibiotic consumption in Serbia; current situation and future direction. Pharmacoepidemiol Drug Saf 2012;21(Suppl 3):98
24. Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract 2000;17 Suppl 1:S11-16
25. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. WHO, Oslo. 2013. Available from: www.whocc.no/atc-ddd-index/
26. Campos J, Ferech M, Lazaro E, et al. Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. J Antimicrob Chemother 2007;60(3):698-701
27. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011; 66(Suppl 6):vi3-12
28. R Project. The R Project for Statistical Computing. Available from: www.r-project. org/
29. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Rev 2011; 4(2):69-79
30. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol 2010;1:141
31. Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8(1): 7-24
32. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy 2009;7(3):137-47
33. Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2011;11(4):469-79
34. Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
35. Moon J, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications. Front Pharmacol 2014;5(Article 219):1-10
36. Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: findings from across Europe and their implications. BMC Med 2014;12(1):98
37. Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. EuroHealth 2011;17:1-4
38. Baumgärtel C, Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel? GaBI J 2012; 1(2):58-68
39. Malmstrom RE, Godman B, Diogene E, et al. Dabigatran-a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in pharmacology 2013;4:39
40. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(6):707-22
41. Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
42. Cizman M, Beovic B. Prirocnik za ambulantno predpisovanje protimikrobnih zdravil. Ljubljana: Arkadija 2002
43. Earnshaw S, Monnet DL, Duncan B, et al. European Antibiotic Awareness Day, 2008-the first Europe-wide public information campaign on prudent antibiotic use: methods and survey of activities in participating countries. Euro Surveill 2009;14(30):19280
44. ZZZS. Recept-The bulletin on drugs covered by Compulsory Health Insurance. 2013. Available from: www.zzzs.si/zzzs/info/egradiva.nsf/o/FEAF7D3377DA0E13C1257 A2C003406A3?OpenDocument
45. ZZZS. Varna raba zdravil. Available from: https://zavarovanec.zzzs.si/wps/portal/portali/azos/domov2013
46. Campbell SM, Godman B, Diogene E, et al. Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic Clin Pharmacol Toxicol. 2014. [Epub ahead of print]
47. Bagari Bizjak N, Fürst J, Kramberger B, et al. Kakovost predpisovanja v druzinski medicini. Recept 2011;9(1):93-5
48. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1):65-83
49. Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011;11(3):343-9
50. Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011;11(1): 121-9
51. Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94(3):221-9
52. Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 2012;104(1):84-91
53. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011; 66(Suppl 6):vi47-56
54. European Centre for Disease Prevention and Control. Trend of antimicrobial consumption of antibacterials for systemic use (ATC group J01) in the community (primary care sector). Available from: www. ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/esac-net-database/pages/trend-consumption-by-country.aspx
55. Cizman M. Measurement units for antibiotic consumption in outpatients. J Antimicrob Chemother 2014;69(10):2877-8
56. Coenen S, Bruyndonckx R, Hens N, et al. Comment on: Measurement units for antibiotic consumption in outpatients. J Antimicrob Chemother 2014;69(12): 3445-6
57. Moe-Byrne T, Chambers D, Harden M, McDaid C. Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review. BMJ open 2014;4(5):e004623
58. Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy 2014;116(2-3):137-46
59. Lejko-Zupanc T, Cizman M, Knez L. Predpisovanje protimikrobnih zdravil v domovih za ostarele. Infektoloski simpozij 2010 Ljubljana. Sekcija za kemoterapijo J 2010;105-14
60. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ (Clinical research ed) 1998;317(7156):465-8
61. Barton S. Using clinical evidence. BMJ (Clinical research ed) 2001;322(7285):503-4